A Study of ES102 (OX40 Agonist) in Patients With Advanced Solid Tumors

Clinical trial NCT04730843 · COMPLETED

Trial details

NCT number: NCT04730843
Sponsor: Elpiscience Biopharma, Ltd.
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Solid Tumors Neoplasms Malignant Tumor

Start date: 2021-04-01
Primary completion: 2024-03-01
Enrollment: 18

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.